

Published in final edited form as:

Nat Med. 2009 September ; 15(9): 1016–1022. doi:10.1038/nm.2015.

A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses

Shaoguang Wu^{1,8}, Ki-Jong Rhee^{1,7,8}, Emilia Albesiano², Shervin Rabizadeh^{3,8}, Xinqun Wu^{1,2}, Hung-Rong Yen^{2,4}, David L Huso⁵, Frederick L Brancati¹, Elizabeth Wick⁶, Florencia McAllister^{1,2}, Franck Housseau², Drew M Pardoll^{1,2}, and Cynthia L Sears^{1,2}

¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

² Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

³ Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

⁴ Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University and Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

⁵ Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

⁶ Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Abstract

The intestinal flora may promote colon tumor formation. Here we explore immunologic mechanisms of colonic carcinogenesis by a human colonic bacterium, enterotoxigenic *Bacteroides fragilis* (ETBF). ETBF that secretes *B. fragilis* toxin (BFT) causes human inflammatory diarrhea but also asymptotically colonizes a proportion of the human population. Our results indicate that whereas both ETBF and nontoxigenic *B. fragilis* (NTBF) chronically colonize mice, only ETBF triggers colitis and strongly induces colonic tumors in multiple intestinal neoplasia (Min) mice. ETBF induces robust, selective colonic signal transducer and activator of transcription-3 (Stat3) activation with colitis characterized by a selective T helper type 17 (T_H17) response distributed between CD4⁺ T cell receptor- $\alpha\beta$ (TCR $\alpha\beta$)⁺ and CD4⁻8⁻TCR $\gamma\delta$ ⁺ T cells. Antibody-mediated blockade of interleukin-17 (IL-17) as well as the receptor for IL-23, a key cytokine amplifying T_H17 responses, inhibits ETBF-induced colitis, colonic hyperplasia and tumor formation. These results show a Stat3- and T_H17-dependent pathway for inflammation-induced

Correspondence should be addressed to C.L.S. (csears@jhmi.edu) or F.H. (fhouse1@jhmi.edu).

⁷Present addresses: Department of Medicine, University of Illinois, Chicago, Illinois, USA (K.-J.R.) and Cedars Sinai Medical Center, Los Angeles, California, USA (S.R.).

⁸These authors contributed equally to this work.

AUTHOR CONTRIBUTIONS

S.W. and K.-J.R. performed the majority of tumorigenesis experiments. E.A., S.R. and E.W. performed Stat experiments. X.W. did most of the mouse breeding and assisted with experiments. H.-R.Y. assisted with conditional CD4 Stat3-KO mouse experiments. D.L.H. evaluated and interpreted the histopathology. F.L.B. contributed the statistical analyses. F.M. performed qRT-PCR experiments. F.H. provided oversight and strategic planning for colonic immunology analyses. D.M.P. and C.L.S. designed the study, reviewed and discussed experiments and wrote the manuscript with input from co-authors.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

Note: Supplementary information is available on the Nature Medicine website.

cancer by a common human commensal bacterium, providing new mechanistic insight into human colon carcinogenesis.

Infection-associated inflammatory processes are known to enhance carcinogenesis in the affected organs. In humans, for example, chronic hepatitis (hepatitis B virus or hepatitis C virus) leads to liver cancer, and chronic *Helicobacter pylori* infection leads to gastric cancer in some individuals^{1,2}. Increased cancer incidence is likewise found in experimental mouse models of both infection-induced and noninfectious inflammation. Conditional knockout mice have shown the importance of nuclear factor- κ B (NF- κ B) signaling not only in the epithelial cells that are the target of transformation but also in myeloid cells that contribute to inflammation^{3,4}. How NF- κ B-induced inflammatory processes drive carcinogenesis is unclear, although IL-6 seems to be pivotal^{5,6}. IL-6 induces the procarcinogenic Stat3 pathway and transcriptionally activates proliferative, antiapoptotic and proangiogenic genes involved in cancer growth⁷. Stat3 signaling organizes the immune microenvironment of tumors to block generation of antitumor immune responses⁸.

In contrast, little information exists on how adaptive immunity, particularly T cell responses, promote cancer. Given that T cell responses generate antitumor responses and more tumors occur in *Rag*^{-/-} mice⁹ and mice with defective interferon signaling¹⁰, chronic innate inflammatory responses are postulated to promote carcinogenesis, whereas T cell-dependent responses are postulated to inhibit carcinogenesis. Three effector pathways of T cell differentiation are now defined: T_H1 responses promoted by Stat1 and Stat4 signaling, T_H2 responses promoted by Stat6 signaling and T_H17 responses promoted by Stat3 signaling^{11,12}. T_H1 responses, driven by IL-12 and characterized by interferon- γ (IFN- γ) production, are typically anticarcinogenic, whereas little is known about the contribution of T_H2 or T_H17 responses to cancer¹⁰.

The role of infectious and inflammatory processes in colon carcinogenesis is of considerable interest, as $\sim 1 \times 10^{13}$ commensal bacteria colonize the colon, with inflammation resulting if colonic epithelial homeostasis is disrupted¹³. Indeed, ulcerative colitis results in predictable development of colon cancer over time. The key role of inflammation in colonic carcinogenesis is emphasized by the diminished tumor formation in multiple intestinal neoplasia (Min) mice (heterozygous for the adenomatous polyposis coli (*Apc*) gene) when Toll-like receptor signaling is abrogated^{14,15}. Because certain human enteric bacteria cause colitis, there is interest in whether any of them can promote colon cancer, analogous to the *H. pylori* promotion of stomach cancer^{1,16}. We are studying a molecular subgroup of *B. fragilis*, ETBF, that produces a metalloprotease toxin termed BFT. ETBF causes acute inflammatory diarrheal disease in children and adults but also asymptotically colonizes up to 20%–35% of adults¹⁷. One study has found higher ETBF colonization in individuals with colon cancer relative to controls without colon cancer¹⁸.

Here we explored potential mechanisms of ETBF-induced colitis and carcinogenesis. We show that ETBF persistently colonizes Min mice with a rapid, strong selective activation of Stat3, whereas the non-toxin-producing NTBF strain colonizes but induces neither colitis nor Stat activation. ETBF colitis is characterized by a selective T_H17 response with markedly increased colonic tumor formation. The T_H17 response directly contributes to ETBF-induced tumorigenesis. These results demonstrate a Stat3- and T_H17-dependent pathway for colon carcinogenesis induced by a common human commensal bacterium, thereby defining a distinct role for adaptive immunity in colon cancer pathogenesis.

RESULTS

ETBF stimulates rapid colitis and colon tumors in Min mice

Min mice colonized with ETBF, but not NTBF, usually developed brief diarrhea by 2–3 d, with resolution of the symptoms by 4–5 d after colonization. Asymptomatic high-level colonization ($\geq 1 \times 10^9$ colony-forming units per g feces) with NTBF or ETBF occurred by day 3 after infection and persisted. Only ETBF-colonized mice showed a marked increase in colonic thickness, inflammation and visible colonic tumors, especially distally, at 4 weeks or later (Fig. 1a–c and Table 1). Histopathology of ETBF-colonized colons confirmed increases in inflammation, hyperplasia and gastrointestinal intraepithelial neoplasia (GIN) foci compared to sham-treated or NTBF-infected colons (Table 1 and Fig. 1c). Linear regression analysis of inflammation or hyperplasia severity supported an association between ETBF-induced inflammation or hyperplasia with GIN and gross colon tumor detection (Fig. 1d). Furthermore, we detected GIN, inflammation and hyperplasia only in ETBF-colonized colons at 1 week after colonization (Fig. 1c). These data suggest that ETBF induces *de novo* tumor formation quickly and may enhance tumor growth rates. Tumors in ETBF-colonized mice were typically laden with inflammatory infiltrates comprised of granulocytes and mononuclear cells not seen in tumors in sham-inoculated or NTBF-colonized Min mice (Fig. 1c). We did not observe an increase in the number of small bowel tumors between experimental groups (data not shown), consistent with the known colonic niche for *B. fragilis* colonization.

ETBF selectively activates Stat3 in the colon

To address the mechanisms of ETBF-induced colitis and carcinogenesis, we assessed activation of Stat proteins. Stat proteins are a family of transcription factors activated by cytokine receptor signaling through tyrosine phosphorylation with nuclear translocation and are central to the regulation of immune responses¹⁹. Stat1 and Stat4 contribute to T_H1-dependent immune responses, whereas Stat6 has a key role in T_H2 responses. Stat3 transduces signals from numerous growth factor and cytokine receptors, is constitutively activated in diverse cancers and is absolutely required for T_H17 cell generation while simultaneously negatively regulating T_H1-mediated inflammation^{11,20–22}.

Using antibodies specific for each phosphorylated Stat protein, we found that only phosphorylated Stat3 (pStat3) was abundant in the colonic mucosa of ETBF-colonized Min mice at 2 d after infection (Fig. 2a), whereas we found only faint pStat3 staining in some sham or NTBF-colonized Min mouse colons (Fig. 2a). We did not detect pStat1, pStat2, pStat5 or pStat6 in the colons of any mouse experimental group (Fig. 2b). We did detect very faint pStat4 signals in some ETBF-colonized Min mice (data not shown). The colons of wild-type (WT) C57BL/6 mice revealed identical pStat staining (Supplementary Fig. 1a), indicating that the highly selective activation of predominantly Stat3 by ETBF colonization is independent of the *Apc* mutation in Min mice.

We used immunohistochemistry to examine the cellular localization and time course of pStat3 activation in ETBF-colonized mice. Stat3 activation occurred in colonic epithelial cells and a subset of infiltrating immune cells in ETBF-colonized Min mice at 2 d to 4 weeks after colonization compared to pStat3 staining in NTBF-colonized or sham mice at the same time points (Fig. 2c and Supplementary Fig. 1b). In addition to nontumorous epithelium, we found 13 tumors of variable sizes in random colon histopathology sections of seven ETBF-colonized Min mice, and all 13 tumors showed intense epithelial cell pStat3 activation and pStat3 staining in a subset of mucosal immune cells (Fig. 2d). The low frequency of tumors in NTBF-colonized or sham-treated Min mice limited our ability to detect tumors in random colon sections. However, in three tumors that we identified in

NTBF-colonized or sham Min mice sections, the pStat3 staining was less consistent and less intense, particularly in the epithelial compartment (Fig. 2d). Thus, beyond inducing tumors in Min colons, ETBF colonization quantitatively alters at least one oncogenic signaling pathway in already established tumors.

ETBF induces dominant colonic T_H17 inflammatory infiltrates

Stat3 signaling is absolutely required for the generation of T_H17 cells, and pStat3 binds the *Il17a* and *Il17f* promoters^{20–22}. We, therefore, wondered whether pStat3 activation by ETBF colonization of Min mice initiates a T_H17 mucosal immune response. FACS analysis ($n = 8$ experiments) of isolated intraepithelial lymphocyte and lamina propria lymphocyte populations showed an approximately four- to fivefold higher number of CD4⁺ T cells in the lamina propria of ETBF-colonized Min mice after 1 week as compared to NTBF- colonized or sham Min mice (data not shown).

ETBF-colonized Min mice indeed developed a strongly skewed T_H17 response characterized by equally contributory IL-17-secreting CD3⁺CD4⁺ and CD3⁺CD4⁻ effector populations in the lamina propria (Fig. 3a,b). We did not find expanded IL-4-producing T cell effector populations, and the modest number of IFN- γ -producing CD3⁺CD4⁺ T cells produced low amounts of IFN- γ (Fig. 3a). In contrast to colonic lymphocytes, CD4⁺TCR $\alpha\beta$ ⁺ and CD8⁺TCR $\alpha\beta$ ⁺ splenic cells isolated from ETBF-colonized mice showed enhanced IFN- γ staining with minimal IL-17 production (Supplementary Fig. 2). We obtained similar results for WT mice (Fig. 3c).

To further identify the IL-17-producing mucosal T cell populations in ETBF-colonized Min mice, we used antibodies to distinguish between classical (TCR $\alpha\beta$ -bearing) and nonclassical (TCR $\gamma\delta$ -bearing) T cells. IL-17 production by CD3⁺CD4⁻ T cells in ETBF-colonized Min or WT mice was attributable to CD3⁺TCR $\gamma\delta$ ⁺ lamina propria cells (Fig. 3d). In contrast, neither lamina propria CD3⁺CD8⁺ cells nor CD3⁻ cells showed intracellular IL-17 staining in ETBF-colonized Min or WT mice (Supplementary Fig. 3).

Beyond Stat3 activation, induction of a T_H17 immune response typically requires IL-6, which, together with transforming growth factor- β (TGF- β) (and augmented by IL-1 β), induces T_H17 differentiation, whereas expansion of IL-17-producing CD4⁺ lymphocytes is promoted by IL-23 (ref. ¹¹). Thus, we examined whether Stat3 is required for ETBF-induced IL-17 production by colonic CD3⁺CD4⁺ T cells isolated from ETBF-colonized WT mice with functional Stat3 knockout in the CD4 T cell compartment (CD4 Stat3-KO). CD4-targeted Stat3 knockout obliterated ETBF induction of IL-17 in this T cell subset, whereas IL-17 persisted in Stat3-competent CD3⁺CD4⁻ T cells (Fig. 3e). Histopathology of ETBF-colonized, CD4-targeted, Stat3-knockout mice revealed significant decreases in inflammation and hyperplasia compared to littermate Stat3-sufficient mice, consistent with the contribution of CD4⁺ cells and Stat3 signaling to ETBF colitis ($P \leq 0.03$, Supplementary Table 1).

By quantitative RT-PCR (qRT-PCR), we detected markedly higher levels of IL-17 messenger RNA in the colonic mucosa of ETBF- colonized Min and WT mice relative to NTBF-colonized mice at 1 week after colonization (Supplementary Fig. 4), consistent with our detection of IL-17 protein in CD4⁺ and CD4⁻ T lymphocytes (Fig. 3b). We also found higher levels of IL-1 β , IL-6, IL-23 and TGF- β mRNA 1 week after ETBF colonization, although the differences in TGF- β mRNA were not significant (Supplementary Fig. 4). A major component of TGF- β regulation occurs after transcription; thus, its mRNA levels are less informative than the mRNA levels of the other cytokines. Lastly, we examined sorted CD3⁺CD4⁺ lymphocytes from Min mice colonized with ETBF or NTBF by qRT-PCR for induction of the gene encoding the T_H17-specific transcription factor, ROR γ ^{t23}, in parallel

with the *Il17a* gene. In CD3⁺CD4⁺ T cells isolated from the colons of ETBF-colonized mice, expression of the gene encoding ROR γ t was tenfold higher (± 2.6 , mean \pm s.e.m.) and *Il17a* gene expression was 21-fold higher (± 2.6) compared to NTBF-colonized mice.

Blockade of IL-17 inhibits ETBF-induced colon tumors

To evaluate the contribution of T_H17 inflammatory cells to ETBF-induced tumor formation in Min mice, we conducted experiments with IL-17A-, IL-23 receptor (IL-23R)- or IFN- γ -neutralizing antibodies. Of the six isoforms of IL-17, IL-17A predominates in humans and mice and in the colonic mucosa after 1 week in ETBF-colonized Min or WT mice (Supplementary Fig. 4). Blockade of IL-17A alone or combined blockade with IL-23R significantly inhibited colon tumor formation at 5 weeks after colonization (Fig. 4a,b). The size distribution of the tumors did not differ between the mice treated with IL-17- and IL-23R-neutralizing antibodies mice compared to isotype controls (Supplementary Fig. 5), emphasizing the contribution of the T_H17 response in tumor initiation and suggesting a minor role in tumor growth rate. In contrast, IFN- γ blockade did not modify ETBF-induced colon tumorigenesis (Fig. 4b). IL-17A blockade did not detectably modify pStat3 levels, as determined by western blotting, nor did it affect the cellular distribution of pStat3, as determined by immunohistochemistry, in the colons of ETBF-colonized WT or Min mice, suggesting that Stat3 activation is upstream of IL-17 induction (Supplementary Fig. 6).

Histopathology revealed marked inhibition of colonic mucosal proliferation with fewer infiltrating leukocytes (Fig. 4c) and GIN foci on random colon tissue sections in ETBF-colonized Min mice treated with IL-17A-blocking antibodies or both IL-17A- and IL-23R-blocking antibodies for 5 weeks compared to ETBF-colonized mice treated with isotype control antibodies for 5 weeks ($P < 0.02$, Supplementary Table 2). We obtained similar results in ETBF-colonized Min mice treated with IL-17A and IL-23R blockade for 1 week (Fig. 4d).

We next examined whether depletion of CD4⁺ or TCR $\gamma\delta$ ⁺ T lymphocytes modifies tumor induction in ETBF-colonized Min mice. Antibody-mediated depletion of CD4⁺ T lymphocytes significantly inhibited the accelerated tumor formation detected 4–6 weeks after ETBF inoculation when compared to ETBF-colonized mice treated with an isotype control antibody ($P = 0.009$), whereas TCR $\gamma\delta$ ⁺ T cell depletion did not modify ETBF-induced colon tumors (Fig. 5). This result provides a direct example that endogenous CD4⁺ T responses contribute to infection-induced carcinogenesis.

DISCUSSION

To our knowledge, the results presented here are the first to demonstrate a direct role for endogenous T cell immune responses in infection-induced carcinogenesis. Our intracellular cytokine staining (ICS) and *in vivo* antibody blockade experiments further implicate a T_H17 response, driven by Stat3 activation, as being crucial to the procarcinogenic effect. This newly described mechanism for infection-induced carcinogenesis may be highly relevant for human carcinogenesis, as, in contrast to all other models of murine colitis, our model uses colonization with a human commensal bacterium, ETBF, that has been epidemiologically linked to colon cancer¹⁸. In this model, essentially all of the IL-17 production is similarly distributed between two T cell subsets, CD4⁺TCR $\alpha\beta$ ⁺ and CD4⁻8⁻TCR $\gamma\delta$ ⁺ T cells. Our *in vivo* depletion experiments emphasize the contribution of classical CD4⁺ T_H17 cells in ETBF-induced colon tumorigenesis, as CD4⁺, but not TCR $\gamma\delta$ ⁺, T cell depletion markedly lowers tumor number. It is still possible that colonic $\gamma\delta$ T cells contribute to the overall tumorigenesis process but that IL-17 production by CD4⁺ T_H17 cells is sufficient to induce tumorigenesis in the absence of $\gamma\delta$ T cells.

In addition to promoting T_H17 development and IL-17 transcription, it has been found that Stat3 activation in the tumor microenvironment inhibits IL-12p35 transcription while enhancing IL-23p19 transcription, thereby shifting the balance from IL-12 to IL-23 (ref. 24). This finding, together with the finding that 9,10-dimethyl-1,2-benzanthracene-induced skin carcinogenesis is diminished in IL-23p19-knockout mice and enhanced in IL-12p35-knockout mice²⁵ as well as the results presented here, suggest that Stat3 potentially promotes a complex procarcinogenic T_H17-type immune response. Beyond the immune compartment, Stat3 activation in the intestinal epithelial compartment also contributes to colon carcinogenesis in the azoxymethane with dextran sulfate sodium model^{26,27}. Tissue-selective Stat3 knockouts on the Min background will be necessary to define the specific roles of Stat3 activation in the various cell types in ETBF colitis.

Although recent work on inflammation-induced carcinogenesis has focused on innate pathways, particularly the NF- κ B and myeloid differentiation factor-88 pathways^{3,14}, little is known about the direct role of adaptive responses in general and T cell responses in particular. In a transgenic model of skin carcinogenesis driven by keratinocyte-specific expression of the human papillomavirus-16 *E6* and *E7* oncogenes, B lymphocytes proved to be major promoters of tumor formation²⁸. Recent adoptive transfer studies of activated T cells into *Rag2*^{-/-} (T and B cell deficient) \times Min mice^{29,30} and *Irfng*^{-/-} TCR transgenic T cells into RIP1-Tag2 (rat insulin promoter driving T antigen expression) transgenic mice that develop islet cell tumors³¹ demonstrated the potential for T cells to promote tumor development. However, to our knowledge, no previous study has yet documented a direct role for endogenous T cell responses as a mechanism for infection-induced cancer.

In contrast, a number of recent studies in *Rag*-knockout mice and mice deficient in interferon signaling show a clear role for lymphocytes in inhibiting cancer development and forcing emerging tumors to edit themselves to evade immune elimination^{10,32}. The finding that the procarcinogenic T cell response in our system is T_H17 mediated suggests that the role of T cell responses in inhibiting or promoting carcinogenesis may depend on the qualitative response. Stat3-driven T_H17 responses, characterized by production of IL-17A in mice and humans and driven by IL-23, are crucial in mucosal inflammatory responses in the lung and gut and are implicated in a number of autoimmune disorders^{11,33-35}.

Although the mechanisms by which ETBF-induced T_H17 responses promote colon carcinogenesis remain undefined, two of our notable histopathological findings in ETBF-colonized colons are the marked epithelial hyperproliferative response and the inflammatory infiltrates, both of which were substantially lessened upon *in vivo* blockade with IL-17- and IL-23R-blocking antibodies. We observed abundant granulocytes in ETBF-colonized colons, consistent with the reported role of T_H17 responses in amplifying granulocytic inflammatory responses¹¹. We are currently evaluating whether IL-17 and other T_H17 cytokines promote colonic epithelial hyperproliferation and whether specific T_H17-induced granulocyte products such as reactive oxygen or nitrogen species contribute to the rapid GIN induction (1 week) by ETBF.

Although the intestinal T_H17 mucosal response to ETBF is not unique, we believe the rapid induction of colonic tumors in young Min mice is unique among reported data on enteric pathogens. Two mouse enteric pathogens, *Citrobacter rodentium* and *Helicobacter hepaticus*, may induce colonic mucosal T_H17 immune responses³³⁻³⁵. However, IL-23 deficiency results in a fatal colitis in mice infected with *C. rodentium* but diminished colitis in mice infected with *H. hepaticus*, suggesting pathogen-specific roles for T_H17 immunity in colitis. Both of these nonhuman enteric pathogens can induce colonic tumors in Min mice, with *C. rodentium* inducing modest colonic tumor induction after 5 months³⁶ and *H. hepaticus*-associated colonic oncogenesis observed only in aged immune-insufficient mice

such as *Rag2*^{-/-} × Min or 129/SvEv *Rag2*^{-/-} mice or mice with, for example, defective TGF signaling^{37,38}. *Salmonella typhimurium* induces T_H17-associated ileitis in rhesus macaques, and uncharacterized commensal flora in mice induce CD4⁺ T_H17 cells with colitis induction upon adoptive transfer to *Rag1*^{-/-} mice, but links to colonic tumor pathogenesis have not been reported^{39,40}.

NTBF strains that do not secrete BFT, the only identified ETBF virulence factor, do not stimulate colonic Stat3 activation, T_H17 mucosal immune responses nor enhance colonic tumor formation in Min mice, suggesting that BFT has a central role in triggering a procarcinogenic colonic mucosal response. Mechanistic data suggest that BFT acts as an oncogenic bacterial toxin through cleavage of E-cadherin, a tumor suppressor protein, triggering β-catenin nuclear signaling and colonic epithelial cell proliferation^{41,42}. BFT also triggers activation of NF-κB, resulting in colonic epithelial cell secretion of proinflammatory cytokines⁴³. We postulate that ETBF is a human oncogenic bacterium, owing to its production of BFT *in vivo*⁴³ and its association with colonic inflammation^{17,44}. To date, one report from Turkey supports this hypothesis¹⁸. Colonic tumor induction by ETBF in human populations would probably require long-term colonization. Although longitudinal carriage of *B. fragilis* is poorly characterized, ETBF is prevalent, at least in some locales, with 4–35% of studied populations showing asymptomatic fecal carriage⁴³.

Commensal colonic bacteria are often cited as crucial environmental factors influencing the development of colorectal cancer, but linkages to specific organisms and the mechanisms promoting oncogenesis have been tenuous¹⁶. We have demonstrated the oncogenic potential of a human colonic commensal organism, and our data are reminiscent of early studies of *H. pylori*, an ancient gastric commensal, colonizing more than 50% of the global population, that routinely induces gastritis and, infrequently, also induces gastric cancer¹. The mucosal immune response to *H. pylori* is also T_H17 skewed, consistent with our observations linking ETBF-induced colonic mucosal T_H17 inflammation to colonic tumor formation⁴⁵. Together, our observations underpin the necessity of human studies to identify potential links between ETBF colonization, colonic Stat3 activation, colonic T_H17 responses and human colorectal cancer.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturemedicine/>.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the Crohn's and Colitis Foundation through a Senior Investigator Award (to C.L.S.) and a Research Fellowship Award (to K.-J.R.), RO1 DK45496 (to C.L.S.), RO1 DK080817 (to C.L.S.), US National Institutes of Health grants (to D.M.P.), Special Projects of Research Excellence grant CA62924, R24 DK64388 (to M. Donowitz, the principal investigator of this grant that provided resource support to this project), RR00171 grant (to D.L.H.), Institutional Training for Pediatricians 5 T32 HD44355 (to G. Dover, the principal investigator of this grant that provided partial salary support to S.R.), Clinical Pharmacology Training Program 2 T32GM066691 (to T. Shapiro, the principal investigator of this grant that provided salary support to F.M.) and F32 DK079509 (to S.R.). This work was also supported by gifts from B. Schwartz, W. and B. Topercer, D. Needle, B. Swartz and the Commonwealth Foundation. D.M.P. is a Januey scholar and holds the Abeloff Chair in Oncology at Johns Hopkins University. We thank J. Wolfe for her assistance with some experiments; L. Myers (formerly Montana State University) for ETBF strain 86-5443-2-2; B. Vogelstein and K. Kinzler (Johns Hopkins University School of Medicine) for Min mice and E. Jaffee (Johns Hopkins University School of Medicine) for GK1.5 antibody.

References

1. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002;347:1175–1186. [PubMed: 12374879]
2. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007;132:2557–2576. [PubMed: 17570226]
3. Greten FR, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 2004;118:285–296. [PubMed: 15294155]
4. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 2005;5:749–759. [PubMed: 16175180]
5. Naugler WE, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science* 2007;317:121–124. [PubMed: 17615358]
6. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends Mol Med* 2008;14:109–119. [PubMed: 18261959]
7. Yu H, Jove R. The STATs of cancer—new molecular targets come of age. *Nat Rev Cancer* 2004;4:97–105. [PubMed: 14964307]
8. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol* 2007;7:41–51. [PubMed: 17186030]
9. Erdman SE, et al. CD4⁺ CD25⁺ regulatory T lymphocytes inhibit microbially induced colon cancer in *Rag2*-deficient mice. *Am J Pathol* 2003;162:691–702. [PubMed: 12547727]
10. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. *Nat Rev Immunol* 2006;6:836–848. [PubMed: 17063185]
11. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu Rev Immunol* 2007;25:821–852. [PubMed: 17201677]
12. Laurence A, O'Shea JJ. T_H-17 differentiation: of mice and men. *Nat Immunol* 2007;8:903–905. [PubMed: 17712339]
13. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol* 2008;8:458–466. [PubMed: 18500230]
14. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. *Science* 2007;317:124–127. [PubMed: 17615359]
15. Su LK, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the *APC* gene. *Science* 1992;256:668–670. [PubMed: 1350108]
16. Hope ME, Hold GL, Kain R, El Omar EM. Sporadic colorectal cancer—role of the commensal microbiota. *FEMS Microbiol Lett* 2005;244:1–7. [PubMed: 15727814]
17. Sears CL, et al. Enterotoxigenic *Bacteroides fragilis* infection is associated with inflammatory diarrhea. *Clin Infect Dis* 2008;47:797–803. [PubMed: 18680416]
18. Toprak NU, et al. A possible role of *Bacteroides fragilis* enterotoxin in the aetiology of colorectal cancer. *Clin Microbiol Infect* 2006;12:782–786. [PubMed: 16842574]
19. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol* 2002;3:651–662. [PubMed: 12209125]
20. Chen Z, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. *Proc Natl Acad Sci USA* 2006;103:8137–8142. [PubMed: 16698929]
21. Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. *Immunity* 2007;26:371–381. [PubMed: 17363300]
22. Harris TJ, et al. Cutting edge: An *in vivo* requirement for STAT3 signaling in T_H17 development and T_H17-dependent autoimmunity. *J Immunol* 2007;179:4313–4317. [PubMed: 17878325]
23. Ivanov II, et al. The orphan nuclear receptor ROR γ at directs the differentiation program of proinflammatory IL-17⁺ T helper cells. *Cell* 2006;126:1121–1133. [PubMed: 16990136]
24. Kortylewski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. *Cancer Cell* 2009;15:114–123. [PubMed: 19185846]
25. Langowski JL, et al. IL-23 promotes tumour incidence and growth. *Nature* 2006;442:461–465. [PubMed: 16688182]

26. Bollrath J, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. *Cancer Cell* 2009;15:91–102. [PubMed: 19185844]
27. Grivennikov S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* 2009;15:103–113. [PubMed: 19185845]
28. de Visser KE, Korets LV, Coussens LM. *De novo* carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. *Cancer Cell* 2005;7:411–423. [PubMed: 15894262]
29. Poutahidis T, et al. Rapid reversal of interleukin-6–dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. *Carcinogenesis* 2007;28:2614–2623. [PubMed: 17724375]
30. Rao VP, et al. Proinflammatory CD4⁺ CD45RB^{hi} lymphocytes promote mammary and intestinal carcinogenesis in Apc^{Min/+} mice. *Cancer Res* 2006;66:57–61. [PubMed: 16397216]
31. Müller-Hermelink N, et al. TNFR1 signaling and IFN- γ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. *Cancer Cell* 2008;13:507–518. [PubMed: 18538734]
32. Koebel CM, et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature* 2007;450:903–907. [PubMed: 18026089]
33. Mangan PR, et al. Transforming growth factor- β induces development of the T_H17 lineage. *Nature* 2006;441:231–234. [PubMed: 16648837]
34. Kullberg MC, et al. IL-23 plays a key role in *Helicobacter hepaticus*–induced T cell–dependent colitis. *J Exp Med* 2006;203:2485–2494. [PubMed: 17030948]
35. Hue S, et al. Interleukin-23 drives innate and T cell–mediated intestinal inflammation. *J Exp Med* 2006;203:2473–2483. [PubMed: 17030949]
36. Newman JV, Kosaka T, Sheppard BJ, Fox JG, Schauer DB. Bacterial infection promotes colon tumorigenesis in Apc^{Min/+} mice. *J Infect Dis* 2001;184:227–230. [PubMed: 11424022]
37. Nagamine CM, et al. *Helicobacter hepaticus* infection promotes colon tumorigenesis in the BALB/c-Rag2^{-/-}Apc^{Min/+} mouse. *Infect Immun* 2008;76:2758–2766. [PubMed: 18411292]
38. Maggio-Price L, et al. *Helicobacter* infection is required for inflammation and colon cancer in SMAD3-deficient mice. *Cancer Res* 2006;66:828–838. [PubMed: 16424015]
39. Raffatellu M, et al. Simian immunodeficiency virus–induced mucosal interleukin-17 deficiency promotes *Salmonella* dissemination from the gut. *Nat Med* 2008;14:421–428. [PubMed: 18376406]
40. Niess JH, Leithauser F, Adler G, Reimann J. Commensal gut flora drives the expansion of proinflammatory CD4 T cells in the colonic lamina propria under normal and inflammatory conditions. *J Immunol* 2008;180:559–568. [PubMed: 18097058]
41. Wu S, Lim KC, Huang J, Saidi RF, Sears CL. *Bacteroides fragilis* enterotoxin cleaves the zonula adherens protein, E-cadherin. *Proc Natl Acad Sci USA* 1998;95:14979–14984. [PubMed: 9844001]
42. Wu S, Morin PJ, Maouyo D, Sears CL. *Bacteroides fragilis* enterotoxin induces c-Myc expression and cellular proliferation. *Gastroenterology* 2003;124:392–400. [PubMed: 12557145]
43. Sears CL. Enterotoxigenic *Bacteroides fragilis*: a rogue among symbiotes. *Clin Microbiol Rev* 2009;22:349–369. [PubMed: 19366918]
44. Rhee KJ, et al. Induction of persistent colitis by a human commensal, enterotoxigenic *Bacteroides fragilis*, in wild-type C57BL/6 mice. *Infect Immun* 2009;77:1708–1718. [PubMed: 19188353]
45. Caruso R, et al. IL-23–mediated regulation of IL-17 production in *Helicobacter pylori*–infected gastric mucosa. *Eur J Immunol* 2008;38:470–478. [PubMed: 18200634]




Figure 1.

ETBF stimulates colonic inflammation and enhances colonic tumor formation in Min mice. (a) Methylene blue–stained representative samples of distal colons of sham control, NTBF-colonized and ETBF-colonized mice showing thickened mucosal folds and excess tumors, visualized in mice colonized with ETBF for 1–2 months. (b) Distribution of visible tumor numbers detected in sham control, NTBF- or ETBF-colonized mice at 4–6 weeks after inoculation. Tumor distributions are shown as box-and-whisker plots. $n = 14$, 10 or 75 for sham control, NTBF or ETBF, respectively. (c) Distal colon histopathology of sham control and NTBF-colonized mice at 4 weeks and ETBF-colonized mice at 1 week and 4 weeks after inoculation. Insets show GIN foci in sham and ETBF-colonized mice. (d) Linear regression analysis of histological scores of ETBF-colonized colons for inflammation and hyperplasia versus visible colon tumor formation or GIN foci. Error bars represent means \pm s.e.m.




Figure 2.

ETBF specifically activates Stat3 in the colons of Min mice. **(a)** Western blot analysis for activated Stat3 (pStat3) in colon samples of sham control Min mice or Min mice colonized with NTBF or ETBF for 2 d. Three individual mice are shown for each experimental condition. β -actin serves as a protein benchmark; protein concentrations per sample were equivalent ($4.3\text{--}4.9\ \mu\text{g}\ \mu\text{l}^{-1}$). The break in the gel (proximal colon) indicates that samples were run on separate gels analyzed in parallel for the same experiment. Data are representative of five sham-inoculated, six NTBF-colonized and six ETBF-colonized Min mice. **(b)** Western blot analysis for pStat proteins in colons of three ETBF-colonized Min mice. Positive controls for each pStat antibody are shown. β -actin served as a protein loading control. **(c)** Immunohistochemistry for pStat3 in distal colon of ETBF-colonized mice 4 weeks after inoculation compared to sham or NTBF-colonized mice. Arrows depict a subset of inflammatory cells in the lamina propria of ETBF-colonized mice that show pStat3 staining (see also Supplementary Fig. 1b). Representative of two sham, four NTBF-colonized and seven ETBF-colonized Min mice. **(d)** Immunohistochemistry for pStat3 in a large colon tumor from an eight-week-old, sham-inoculated Min mouse and a similar-sized colon tumor in a Min mouse colonized with ETBF for 4 weeks. Arrows designate pStat3 staining of inflammatory cells in the interstitium.




Figure 3.

ETBF, but not NTBF, induces IL-17–producing CD3⁺CD4⁺ T lymphocytes and $\gamma\delta$ T lymphocytes in the colon lamina propria of Min and WT mice 1 week after NTBF or ETBF inoculation. **(a)** ICS for IL-17, IFN- γ and IL-4 in CD3⁺CD4⁺ T lymphocytes of Min mice. Dot plots are derived from the CD3⁺CD4⁺ gate. **(b)** ICS for IL-17 in CD3⁺CD4⁺ and CD3⁺CD4⁻ lymphocytes from the lamina propria of ETBF-colonized Min mice. Dot plots are derived from CD3⁺ gate. **(c)** ICS for IL-17 and IFN- γ in CD3⁺CD4⁺ and CD3⁺CD4⁻ T lymphocytes of C57BL/6 mice. Dot plots are derived from CD3⁺CD4⁺ and CD3⁺ gates. **(d)** ICS for IL-17 in $\gamma\delta$ T cells from the lamina propria of ETBF-colonized Min mice. Dot plots are derived from CD3⁺CD4⁻ gate. **(e)** ICS staining in CD3⁺CD4⁺ and CD3⁺CD4⁻ lymphocytes from WT and CD4 Stat3-KO C57BL/6 mice. Dot plots are derived from the CD3⁺ gate. Each panel is representative of at least three independent experiments except **e** (two independent experiments). The numbers inside the plots indicate the percentage of the cell population showing the quadrant characteristic.




Figure 4.

Blockade of IL-17 and IL-23R, but not IFN- γ , inhibits ETBF-induced colonic tumor formation in Min mice. **(a)** Methylene blue–stained representative samples of distal colons of mice colonized with ETBF for 5 weeks and treated with IL-17 and IL-23R blocking antibodies or isotype control antibodies. **(b)** Depiction of tumor number distribution by box-and-whisker plots in ETBF-colonized mice treated with isotype-matched antibodies (IgG + ET; experimental positive control) and ETBF-colonized mice treated with IL-17– (IL-17A + ET), IL-17– and IL-23R– (IL-17 + IL-23R + ET) or IFN- γ – (IFN- γ + ET) blocking antibodies after 5 weeks. Sham-inoculated mice served as an experimental negative control. Top, $n = 24$ for IgG + ET, 8 for IL-17 + ET, 14 for IL-17 + IL-23R + ET and 7 for sham. Bottom, $n = 9$ for IgG + ET and 11 for IFN- γ + ET. **(c)** Histopathology of distal colon tumors in Min mice colonized with ETBF for 5 weeks and treated with isotype control antibodies (left) or IL-17– and IL-23R– blocking antibodies (right). Two representative mice of 24 (isotype control) or 14 (IL-17– blocking and IL-23R– blocking antibody treated) per treatment group are shown. **(d)** Histopathology of distal colon of Min mice colonized with ETBF for 1 week and treated with isotype control antibody (center) or IL-17– and IL-23R– blocking antibodies (right). Left image shows the distal colon of a sham control Min mouse. Micrographs are representative of three sham control, five ETBF and isotype control antibody–treated and four ETBF, IL-17– and IL-23R– neutralizing antibody–treated mice.




Figure 5.

$CD4^+$, but not $\gamma\delta^+$, T cell depletion inhibits tumor formation in ETBF-colonized Min mice. $CD4^+$ T cells (CD4 + ET) or $\gamma\delta$ T cells (TCR $\gamma\delta$ + ET) were depleted in ETBF-colonized mice using specific monoclonal antibodies and compared to ETBF-colonized mice treated in parallel with IgG isotype control antibodies (IgG + ET). Distribution of tumor numbers is shown using box-and-whisker plots. Left, $n = 22$ for IgG + ET and 24 for CD4 + ET. Right, $n = 9$ for IgG + ET and 11 for TCR $\gamma\delta$ + ET.

Table 1

Min mouse colon histological scores 1 week and 4–6 weeks after ETBF or NTBF colonization

	Median (range)			
	Inflammation	Hyperplasia	GIN	Gross tumors
1 week				
Sham (<i>n</i> =6)	0 (0–0)	1 (0–1)	0 (0–0)	NA
NTBF (<i>n</i> =4)	0 (0–0)	0 (0–0)	0 (0–0)	NA
ETBF (<i>n</i> =16)	2 (0–3) ^a	3 (2–4) ^b	1.5 (0–4) ^c	NA
4–6 weeks				
Sham (<i>n</i> =9)	0 (0–1)	0 (0–1)	0 (0–0)	2 (0–8)
NTBF (<i>n</i> =5)	0 (0–0)	0 (0–1)	0 (0–0)	3 (2–4)
ETBF (<i>n</i> =59)	1 (0–3) ^d	2 (1–4) ^e	1 (0–16) ^f	9 (2–49) ^g

NA, not applicable.

^a*P* < 0.015 versus 1 week sham and NTBF; independent comparisons.^b*P* < 0.0004 versus 1 week sham and NTBF; independent comparisons.^c*P* < 0.042 versus 1 week sham and NTBF; independent comparisons.^d*P* < 0.0006 versus 4–6 week sham and NTBF; independent comparisons.^e*P* < 0.0004 versus 4–6 week sham and NTBF; independent comparisons.^f*P* < 0.018 versus 4–6 week sham and *P* = 0.10 versus NTBF; independent comparisons.^g*P* < 0.0005 versus 4–6 week sham and NTBF; independent comparisons.